Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.


Investor type Venture Capital
Founders Ben Lin Feng Li


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 155
Average round size
The average size of a deal this fund participated in
Portfolio companies 107
Rounds per year 22.14
Lead investments 14
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 6
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Artificial Intelligence
  • E-Commerce
  • Internet
  • Biotechnology
  • Health Care

FREES FUND appeared to be the VC, which was created in 2015. The company was established in Asia in China. The leading representative office of defined VC is situated in the Beijing.

The fund was created by Ben Lin, Feng Li. We also calculated 4 valuable employees in our database.

This FREES FUND works on 27 percentage points less the average amount of lead investments comparing to the other organizations. When the investment is from FREES FUND the average startup value is 500 millions - 1 billion dollars. The real fund results show that this VC is 8 percentage points more often commits exit comparing to other companies. The fund is generally included in 13-24 deals every year. The increased amount of exits for fund were in 2016. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 10 - 50 millions dollars.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the FREES FUND, startups are often financed by ZhenFund, Yunqi Partners, TAL Education Group. The meaningful sponsors for the fund in investment in the same round are ZhenFund, Shunwei Capital, Matrix Partners China. In the next rounds fund is usually obtained by IDG Capital, Matrix Partners China, ZhenFund.

Besides, a startup needs to be aged 2-3 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Among the most popular fund investment industries, there are Internet, Education. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight Unity Technologies, Huasheng Haoche, Club Factory.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of FREES FUND:
Typical Co-investors
FREES FUND is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after FREES FUND:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Artificial Intelligence
18 Sep 2022 Haidian, Beijing, China


07 Sep 2022 Minhang, Shanghai, China


Autonomous Vehicles
03 Aug 2022 Nanjing, Jiangsu, China

Kunmai Medical

Medical Device
20 Jul 2022 Beijing, Beijing, China


$6M31 May 2022 Burlingame, California, United States


Autonomous Vehicles
19 Apr 2022 Nanjing, Jiangsu, China

METiS Pharmaceuticals

Artificial Intelligence
$150M06 Apr 2022 Shangcheng District, Zhejiang, China

METiS Therapeutics

Health Care
$75M05 Apr 2022 Cambridge, Massachusetts, United States


10 Mar 2022 Pudong, Shandong, China
OnQuality Pharmaceuticals Announces Closing of $35 Million Series A+ Financing

– OnQuality Pharmaceuticals LLC (“OnQuality”), a targeted cancer supportive care company developing medications to address specific side effects and improve the quality of life for patients receiving anti-cancer medications, today announced the closing of its Series A+ financing round securing an additional $20 million in funding. This brings the total amount of capital raised in Series A and A+ to $35 million.
– This financing round included participation from Shiyu Capital, Matrix Partners China, BioTrack Capital, CASH Capital, Sinovation Ventures, FreeS Fund, and additional biotech veterans.
– Proceeds from the financing will support the ongoing Phase II clinical trial of the company’s leading compound OQL011, as well as multiple additional targeted cancer supportive care programs anticipated to enter different phases of clinical development over the next 18 months.
OnQuality also announced the appointment of pharmaceutical executive Michael McCullar, Ph.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent FREES FUND?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: